RxDoctor Payments Data

Christopher Wong, MD

Internal Medicine · San Francisco, CANPI 1457529174

Payments from drug & device makers

$3,004in general payments, 2019–2025

Across 64 payments — averaging $46.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$808
  • Boston Scientific$552
  • Abbott$539
  • GSK$314
  • Amarin Pharma, Inc.$299
  • Abiomed$138
  • plus $354 from 8 others

What the payments were for

  • Consulting fees$73024%
  • Food & beverage$1,65555%
  • Education$61821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,004 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$220,351
Medicare patients
472
Services billed
1,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide94$176,303
EliquisApixaban111$152,438
JanuviaSitagliptin Phosphate81$101,515
JardianceEmpagliflozin65$76,073
XareltoRivaroxaban49$67,970
Janumet XrSitagliptin Phos/Metformin Hcl34$47,910
CreonLipase/Protease/Amylase14$30,499
BriviactBrivaracetam14$17,331
TradjentaLinagliptin13$16,623
Tenofovir Disoproxil Fumarate61$13,767
Entecavir17$12,099
JanumetSitagliptin Phos/Metformin Hcl16$12,039
Atorvastatin Calcium980$8,976
Losartan Potassium598$5,739
SynthroidLevothyroxine Sodium60$5,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$808$176,30394 claims
PfizerEliquis$29$152,438111 claims
AbbVieCreon, Synthroid$13$35,81774 claims
GSKBreo Ellipta$314$4,35011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →